Filtered By:
Infectious Disease: COVID-19

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 157 results found since Jan 2013.

Computational study and design of effective siRNAs to silence structural proteins associated genes of Indian SARS-CoV-2 strains
Comput Biol Chem. 2022 Apr 29;98:107687. doi: 10.1016/j.compbiolchem.2022.107687. Online ahead of print.ABSTRACTSARS-CoV-2 is a highly transmissible and pathogenic coronavirus that first emerged in late 2019 and has since triggered a pandemic of acute respiratory disease named COVID-19 which poses a significant threat to all public health institutions in the absence of specific antiviral treatment. Since the outbreak began in March 2020, India has reported 4.77 lakh Coronavirus deaths, according to the World Health Organization (WHO). The innate RNA interference (RNAi) pathway, on the other hand, allows for the development...
Source: Computational Biology and Chemistry - May 10, 2022 Category: Bioinformatics Authors: Premnath Madanagopal Harshini Muthukumar Kothai Thiruvengadam Source Type: research

Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection
J Microbiol Immunol Infect. 2023 Mar 8:S1684-1182(23)00068-3. doi: 10.1016/j.jmii.2023.02.010. Online ahead of print.ABSTRACTRNA interference (RNAi) is an emerging and promising therapy for a wide range of respiratory viral infections. This highly specific suppression can be achieved by the introduction of short-interfering RNA (siRNA) into mammalian systems, resulting in the effective reduction of viral load. Unfortunately, this has been hindered by the lack of a good delivery system, especially via the intranasal (IN) route. Here, we have developed an IN siRNA encapsulated lipid nanoparticle (LNP) in vivo delivery system...
Source: Journal of Microbiology, Immunology, and Infection - March 18, 2023 Category: Microbiology Authors: Aroon Supramaniam Yaman Tayyar Daniel T W Clarke Gabrielle Kelly Dhruba Acharya Kevin V Morris Nigel A J McMillan Adi Idris Source Type: research

Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs
Despite significant efforts, there are currently no approved treatments for COVID-19. However, biotechnological approaches appear to be promising in the treatment of the disease. Accordingly, nucleic acid-based treatments including aptamers and siRNAs are candidates that might be effective in COVID-19 treatment. Aptamers can hamper entry and replication stages of the SARS-CoV-2 infection, while siRNAs can cleave the viral genomic and subgenomic RNAs to inhibit the viral life cycle and reduce viral loads. As a conjugated molecule, aptamer–siRNA chimeras have proven to be dual-functioning antiviral therapy, acting both as ...
Source: Frontiers in Microbiology - November 8, 2021 Category: Microbiology Source Type: research

Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread
Nucleic Acids Res. 2021 Dec 20:gkab1248. doi: 10.1093/nar/gkab1248. Online ahead of print.ABSTRACTA promising approach to tackle the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) could be small interfering (si)RNAs. So far it is unclear, which viral replication steps can be efficiently inhibited with siRNAs. Here, we report that siRNAs can target genomic RNA (gRNA) of SARS-CoV-2 after cell entry, and thereby terminate replication before start of transcription and prevent virus-induced cell death. Coronaviruses replicate via negative sense RNA intermediates using a unique discontinuous transcription process. ...
Source: Cell Research - December 20, 2021 Category: Cytology Authors: Shubhankar Ambike Cho-Chin Cheng Martin Feuerherd Stoyan Velkov Domizia Baldassi Suliman Qadir Afridi Diana Porras-Gonzalez Xin Wei Philipp Hagen Nikolaus Kneidinger Mircea Gabriel Stoleriu Vincent Grass Gerald Burgstaller Andreas Pichlmair Olivia M Merke Source Type: research

Expression of MACC1 protein in gastric cancer and its effect on proliferation and invasion of gastric cancer cells.
CONCLUSION: MACC1 was highly expressed in gastric cancer tissues. The expression of MACC1 was related to the differentiation degree, infiltration depth, lymph node metastasis and staging of gastric cancer. Down-regulation of MACC1 could inhibit the proliferation and invasion of gastric cancer cells. This study provided a certain biological basis for early clinical prediction, diagnosis and treatment of gastric cancer. PMID: 32415936 [PubMed - as supplied by publisher]
Source: Cellular and Molecular Biology - May 18, 2020 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

RNAi suppressor: The hidden weapon of SARS-CoV.
Abstract The two biological evidences to endorse the antiviral activity of RNA interference (RNAi) are biogenesis of viral-siRNA (v-siRNA) by the host and encoding of RNAi-suppressor protein by viral genome. It has been recently established that mammals and mammalian cell lines mount antiviral RNAi to defend themselves against the invading viruses. The large part of viral pathogenicity is also due to the RNAi suppressor proteins. In this context it is only natural to ask what kinds of RNAi suppressors are encoded by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the central character of the pres...
Source: Journal of Biosciences - July 29, 2020 Category: Biomedical Science Authors: Karjee S, Mukherjee SK Tags: J Biosci Source Type: research

City of Hope and Griffith University develop direct-acting antiviral to treat COVID-19
(City of Hope) An international team of scientists have developed an experimental direct-acting antiviral therapy to treat COVID-19. Traditional antivirals reduce symptoms and help people recover earlier. This next-generation antiviral approach used gene-silencing RNA technology called siRNA (small-interfering RNA) to attack the virus' genome directly, which stops the virus from replicating, as well as lipid nanoparticles designed at Griffith University and City of Hope to deliver the siRNA to the lungs, the critical site of infection.
Source: EurekAlert! - Biology - May 18, 2021 Category: Biology Source Type: news

Viruses, Vol. 13, Pages 2030: Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence
Drosten Jens Kurreck Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected almost 200 million people worldwide and led to approximately 4 million deaths as of August 2021. Despite successful vaccine development, treatment options are limited. A promising strategy to specifically target viral infections is to suppress viral replication through RNA interference (RNAi). Hence, we designed eight small interfering RNAs (siRNAs) targeting the highly conserved 5’-untranslated region (5’-UTR) of SARS-CoV-2. The most promising candidate identified in initial reporter assays, termed siCoV6, targets the ...
Source: Viruses - October 8, 2021 Category: Virology Authors: Beatrice Tolksdorf Chuanxiong Nie Daniela Niemeyer Viola R öhrs Johanna Berg Daniel Lauster Julia M. Adler Rainer Haag Jakob Trimpert Benedikt Kaufer Christian Drosten Jens Kurreck Tags: Article Source Type: research

Development of Lipid Nanoparticles for the Delivery of Macromolecules Based on the Molecular Design of pH-Sensitive Cationic Lipids
Chem Pharm Bull (Tokyo). 2021;69(12):1141-1159. doi: 10.1248/cpb.c21-00705.ABSTRACTConsiderable efforts have been made on the development of lipid nanoparticles (LNPs) for delivering of nucleic acids in LNP-based medicines, including a first-ever short interfering RNA (siRNA) medicine, Onpattro, and the mRNA vaccines against the coronavirus disease 2019 (COVID-19), which have been approved and are currently in use worldwide. The successful rational design of ionizable cationic lipids was a major breakthrough that dramatically increased delivery efficiency in this field. The LNPs would be expected to be useful as a platform...
Source: Chemical and Pharmaceutical Bulletin - December 2, 2021 Category: Drugs & Pharmacology Authors: Yusuke Sato Source Type: research